Histocell

Executive Summary

Histocell is a Spanish regenerative medicine biopharmaceutical company based in Bilbao, founded in 2004. The company focuses on developing and manufacturing cell therapies, biological products, innovative medical devices, and dermocosmetic products. It operates a GMP-certified Contract Development and Manufacturing Organization (CDMO) facility for advanced therapies and has a strategic partnership with REPROCELL to manufacture clinical-grade iPSCs. Histocell’s diversified portfolio spans therapeutic, device, and cosmetic segments, reducing single-point risk. Its CDMO services provide recurring revenue while its proprietary pipeline targets regenerative medicine applications. The company’s expertise in cell therapy and iPSC manufacturing positions it well in the growing advanced therapies market. As a private company, financial details are limited, but its established GMP facility and partnerships suggest a solid operational foundation.

Upcoming Catalysts (preview)

• Q3 2026Phase 2/3 trial results for lead cell therapy candidate40% success
• Q4 2026New CDMO contract with a major biopharma50% success
• Q2 2026Milestone achievement in iPSC manufacturing partnership with REPROCELL70% success